Reports
1 reportQuarterly reports, annual reports and year-end reports from A3P Biomedical, newest first.
Brief summary – A3P Biomedical Annual Report 2025
2025 is described as a year of major scientific and strategic progress, but also of lessons about commercialisation in markets with complex reimbursement.
A3P Biomedical in the catalogue
The company's own page has the share price, valuation, owners and the reports published for trading.
Go to A3P BiomedicalOther news about A3P Biomedical
6 postsEverything we have written about A3P Biomedical, newest first. The reports stand on their own at the top and the rest of the news below them — acquisitions, share issues, partnerships and what the company itself has announced. You will find the share price, valuation and company data on the company's own page.
A3P Biomedical: study shows 90 per cent sensitivity for Stockholm3 — net sales down 61 per cent
Net sales amounted to 2.8 MSEK in the second quarter, a decrease of 61 per cent that the company mainly attributes to sales being conducted in the form of pilot projects.
Stockholm3 included in NCCN guidelines for Prostate Cancer Early Detection
As of June 2025, Stockholm3 has been included as a diagnostic tool for prostate biopsy decisions in the updated NCCN Clinical Practice Guidelines for Prostate Cancer Early Detection.
A3P Biomedical appoints Christopher O’Connell as Board Director
A3P Biomedical AB (publ) (A3P) announces that Christopher O’Connell has been appointed to the Board of Directors, bringing the company extensive strategic and operational experience.
Stockholm3 outperforms other prostate cancer biomarkers and risk calculators
A recently published article in the Journal of Urology highlights how effective Stockholm3 is at improving the diagnosis of prostate cancer.
Stockholm3 study awarded best abstract in session at the 2025 European Association of Urology congress
An independent international multicentre study of Stockholm3, led by Professor Derya Tilki, received the Best Abstract award in the session on diagnostic and prognostic biomarkers for prostate cancer at the European Association of Urology (EAU) annual congress 2025…
A3P Biomedical and BioAgilytix establish partnership for Stockholm3 in the US
A3P Biomedical AB, a Swedish diagnostics company focused on prostate cancer, and BioAgilytix, a global provider of bioanalysis, have entered into a collaboration to launch the Stockholm3 test as a laboratory-developed test (LDT) in the…
